Quoin Pharmaceuticals, Ltd. (QNRX)Healthcare | Biotechnology | Ashburn, United States | NasdaqCM
4.10 USD
-0.05
(-1.205%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 4.17 +0.07 (1.707%) ⇧ (Oct. 14, 2026, 7:58 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 6:18 a.m. EDT
The immediate outlook is bearish due to a crushing technical breakdown; the stock has lost nearly 80% of its value over the last year and is currently trading significantly below its 50-day and 200-day moving averages, indicating heavy selling pressure and a lack of immediate support. While recent headlines celebrate a funding deal and regulatory approval, these catalysts have failed to arrest the decline, leaving the price in freefall territory with no clear upward momentum to justify a short-term entry. Looking further ahead, the fundamental picture is dire: the company is burning through cash with negative free cash flow and negative operating cash flow, while profitability metrics like return on equity and return on assets are deeply negative. The balance sheet shows significant debt relative to equity, and despite a recent uptick in annual returns, the multi-year trajectory reveals a catastrophic loss of value, suggesting the market views the business model as fundamentally broken rather than temporarily distressed. There is absolutely no dividend income to offset these risks, making this a high-risk speculative vehicle unsuitable for capital preservation. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.304312 |
| AutoARIMA | 0.307109 |
| MSTL | 0.310543 |
| AutoTheta | 0.336427 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 5.74 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.156 |
| Excess Kurtosis | -1.40 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 51.46 |
| Market Cap | 19,697,060 |
| Forward P/E | -1.29 |
| Beta | 1.75 |
| Previous Name | Cellect Biotechnology Ltd. |
| Website | https://quoinpharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7282253 |
| Address1 | 42,127 Pleasant Forest Court |
| All Time High | 1,417,500.0 |
| All Time Low | 3.25 |
| Ask | 4.57 |
| Ask Size | 1 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 49,580 |
| Average Daily Volume3 Month | 541,793 |
| Average Volume | 541,793 |
| Average Volume10Days | 49,580 |
| Beta | 1.745 |
| Bid | 4.46 |
| Bid Size | 5 |
| Book Value | 1.958 |
| City | Ashburn |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.1 |
| Current Ratio | 1.76 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.29 |
| Day Low | 3.975 |
| Debt To Equity | 51.46 |
| Display Name | Quoin Pharmaceuticals |
| Dividend Date | 1,571,788,800 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,710,419,400 |
| Earnings Call Timestamp Start | 1,710,419,400 |
| Earnings Timestamp End | 1,754,915,400 |
| Earnings Timestamp Start | 1,754,483,400 |
| Ebitda | -19,045,144 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.028 |
| Enterprise Value | -541,835 |
| Eps Current Year | -7.17 |
| Eps Forward | -3.185 |
| Eps Trailing Twelve Months | -5.67 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.6832 |
| Fifty Day Average Change | -1.5832 |
| Fifty Day Average Change Percent | -0.27857545 |
| Fifty Two Week Change Percent | -72.82253 |
| Fifty Two Week High | 23.5 |
| Fifty Two Week High Change | -19.4 |
| Fifty Two Week High Change Percent | -0.8255319 |
| Fifty Two Week Low | 3.25 |
| Fifty Two Week Low Change | 0.8499999 |
| Fifty Two Week Low Change Percent | 0.26153845 |
| Fifty Two Week Range | 3.25 - 23.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,470,058,200,000 |
| Float Shares | 1,934,769 |
| Forward Eps | -3.185 |
| Forward P E | -1.2872841 |
| Free Cashflow | -7,999,400 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 4 |
| Fullday Change | 0.2999997 |
| Fullday Change Percent | 7.2289085 |
| Fullday Price | 4.1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03667 |
| Held Percent Institutions | 0.27808002 |
| Implied Shares Outstanding | 4,804,161 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,744,156,800 |
| Last Split Factor | 1:35 |
| Long Business Summary | Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc. |
| Long Name | Quoin Pharmaceuticals, Ltd. |
| Market | us_market |
| Market Cap | 19,697,060 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_593010770 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | -18,665,316 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 13,556,818 |
| Number Of Analyst Opinions | 7 |
| Open | 4.11 |
| Operating Cashflow | -15,273,747 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 703 980 4182 |
| Post Market Change | 0.07000017 |
| Post Market Change Percent | 1.7073213 |
| Post Market Price | 4.17 |
| Post Market Time | 1,792,022,288 |
| Prev Name | Cellect Biotechnology Ltd. |
| Previous Close | 4.15 |
| Price Eps Current Year | -0.57182705 |
| Price Hint | 4 |
| Price To Book | 2.0939734 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.633 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | -0.0500002 |
| Regular Market Change Percent | -1.20482 |
| Regular Market Day High | 4.29 |
| Regular Market Day Low | 3.975 |
| Regular Market Day Range | 3.975 - 4.29 |
| Regular Market Open | 4.11 |
| Regular Market Previous Close | 4.15 |
| Regular Market Price | 4.1 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 159,326 |
| Return On Assets | -1.1460199 |
| Return On Equity | -5.75732 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,804,161 |
| Shares Percent Shares Out | 0.0136 |
| Shares Short | 65,473 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 526,654 |
| Short Name | Quoin Pharmaceuticals, Ltd. |
| Short Percent Of Float | 0.0136 |
| Short Ratio | 0.54 |
| Source Interval | 15 |
| State | VA |
| Symbol | QNRX |
| Target High Price | 35.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 20.71429 |
| Target Median Price | 20.0 |
| Total Cash | 10,800,082 |
| Total Cash Per Share | 5.377 |
| Total Debt | 2,023,733 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.67 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.64439 |
| Two Hundred Day Average Change | -2.5443902 |
| Two Hundred Day Average Change Percent | -0.38293812 |
| Type Disp | Equity |
| Volume | 159,326 |
| Website | https://quoinpharma.com |
| Zip | 20,148-7349 |